The promise and potential hazards of adenovirus gene therapy

Gut

Volumn 48, Issue 5, 2001, Pages 733-736

  Young, L S ^a   Mautner, V ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; ENZYME DEFICIENCY; GENE TARGETING; GENE THERAPY; PRIORITY JOURNAL; REVIEW;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER DISEASES; NEUTROPHIL INFILTRATION; REPRODUCIBILITY OF RESULTS;

EID: 0035033843     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.48.5.733     Document Type: Review

References (60)

1. Biomedicine - Gene therapy on trial
2. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
3. Obstacles and advances in non-viral gene delivery
4. Adenoviruses
5. Infection of mouse liver by human adenovirus type 5
6. Regulation of TNF-mediated cell death and inflammation by human adenovirus
7. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
8. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo
9. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity
10. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2
11. Assessment of efficiency and safety of adenovirus-mediated gene transfer into normal and damaged murine livers
12. Receptors mediating adenovirus attachment and internalization
13. Specificity of the mouse cytotoxic lymphocyte-T response to adenovirus 5-E1 a is immunodominant in h-2b, but not in h-2d or h-2k mice
14. Anti-adenovirus type 5 cytotoxic lymphocyte T-immunodominant epitopes are encoded by the E1a gene
15. Identification of adenovirus E1a regions which affect MHC class-I expression and susceptibility to cytotoxic T-lymphocytes
16. MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells
17. Characterization of human proliferative T-cell responses to adenovirus
18. Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro
19. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
20. Sero-switch adenovirus-mediated in-vivo gene-transfer - Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype
21. Phase I trial of recombinant adenovirus gene transfer in lung cancer - Longitudinal study of the immune responses to transgene and viral products
22. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
23. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma
24. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues
25. Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration
26. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung
27. An adenovirus type-2 glycoprotein blocks cell-surface expression of human histocompatibility class-I antigens
28. Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K
29. Role of early region 3 (E3) in pathogenesis of adenovirus disease
30. Association of human class I MHC alleles with the adenovirus E3/19K protein
31. Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver
32. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression
33. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells
34. Adenovirus E3 proteins: 14.7K, RID, and gp 19K inhibit immune-induced cell death; Adenovirus death protein promotes cell death
35. Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic
36. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
37. Biology of adenovirus vectors with E1 and e4 deletions for liver-directed gene therapy
38. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted
39. A high capacity adenovirus vector with all viral genes deleted results in improved in vivo expression and decreased toxicity
40. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and betagalactosidase
41. Persistence in muscle of an adenoviral vector that lacks all viral genes
42. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene
43. Recombinant adenoviruses with large deletions generated by cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo
44. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging
45. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal
46. Adenovirus vectors for gene delivery
47. Circumvention of immunity to the adenovirus major coat protein hexon
48. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism
49. Targeted gene delivery by tropism-modified adenoviral vectors
50. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor
51. Addition of a short peptide ligand to the adenovirus fiber protein
52. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism
53. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins
54. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection
55. Targeting adenovirus
56. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae
57. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR
58. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein
59. A system for the propagation of adenoviral vectors with genetically modified receptors
60. Adenovirus vector pseudotyping in fiber-expressing cell lines: Improved transduction of Epstein-Barr virus-transformed B cells